Clinical Trials
13 trialsNCT03333343 2026-01-16
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Novartis
Phase 1 Active not recruiting
NCT03742349 2025-05-18
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Novartis
Phase 1 Terminated
NCT05435846 2024-06-11
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
University of California, San Francisco
Phase 1 Terminated
NCT02386826 2023-09-21
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01911507 2021-10-13
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
University of California, Davis
Phase 1 Completed
NCT01324479 2020-12-19
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01546428 2020-12-19
A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02925104 2020-12-19
A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
Novartis
Phase 1 Completed
NCT02474537 2020-12-10
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
Novartis
Phase 1 Completed
NCT02520752 2020-12-10
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02626234 2020-12-10
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02205398 2019-01-22
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Novartis
Phase 1 Terminated
NCT01072266 2017-11-22
A Dose-escalation Study in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1 Completed